Maxim Group Issues Positive Forecast for OS Therapies (NYSE:OSTX) Stock Price

OS Therapies (NYSE:OSTX) had its price target raised by stock analysts at Maxim Group from $8.00 to $15.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 247.22% from the stock’s previous close.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $20.00 price target on shares of OS Therapies in a research note on Wednesday.

OS Therapies Stock Down 0.9 %

Shares of NYSE:OSTX traded down $0.04 during trading on Thursday, hitting $4.32. 448,648 shares of the company were exchanged, compared to its average volume of 1,991,653. OS Therapies has a fifty-two week low of $1.58 and a fifty-two week high of $7.00. The firm has a fifty day simple moving average of $3.29.

Institutional Trading of OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC acquired a new stake in OS Therapies Inc (NYSE:OSTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.